CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 189 enrolled
Drug / intervention
BBI-4000 Gel, 5% +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02336503
NCT02336503Phase 2Completed
CompareCT.gov

A Multicenter, Randomized, Double Blind, Vehicle-Controlled Study to Evaluate the Safety and Effect on Sweat Production of 3 Concentrations of Topically Applied BBI-4000 in Subjects With Axillary Hyperhidrosis

Botanix Pharmaceuticals·interventional·Posted Jan 13, 2015·Updated Mar 15, 2023

In Brief

A Phase 2 clinical trial evaluating BBI-4000 Gel, 5%, BBI-4000 Gel, 10%, and 2 other interventions for Hyperhidrosis. Completed, enrolled 189 participants across 12 sites.

Detailed Summary

To assess the safety and efficacy of 3 doses of BBI-4000 and vehicle (4 treatment arms), when applied once a day for 4 weeks, for the treatment of axillary hyperhidrosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperhidrosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 13, 2015
Enrollment StartMar 10, 2015
Primary CompletionNov 5, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 11.5 years ago

Interventions

BBI-4000 Gel, 5%drug

BBI-4000 Gel, 5%

BBI-4000 Gel, 10%drug

BBI-4000 Gel, 10%

BBI-4000 Gel, 15%drug

BBI-4000 Gel, 15%

Vehicledrug

Placebo, BBI-4000 Gel, 0%